Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Mechanisms of resistance to CAR T cell therapy.

Shah NN, Fry TJ.

Nat Rev Clin Oncol. 2019 Jun;16(6):372-385. doi: 10.1038/s41571-019-0184-6. Review.

PMID:
30837712
2.

The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.

Jin Z, Xiang R, Qing K, Li X, Zhang Y, Wang L, Zhu H, Mao Y, Xu Z, Li J.

Ann Hematol. 2018 Aug;97(8):1327-1335. doi: 10.1007/s00277-018-3368-8. Epub 2018 May 15.

PMID:
29766234
3.

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells.

Kueberuwa G, Zheng W, Kalaitsidou M, Gilham DE, Hawkins RE.

J Vis Exp. 2018 Oct 16;(140). doi: 10.3791/58492.

4.

CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.

Pehlivan KC, Duncan BB, Lee DW.

Curr Hematol Malig Rep. 2018 Oct;13(5):396-406. doi: 10.1007/s11899-018-0470-x. Review.

PMID:
30120708
5.

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.

Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, Raffeld M, Feldman S, Lu L, Li YF, Ngo LT, Goy A, Feldman T, Spaner DE, Wang ML, Chen CC, Kranick SM, Nath A, Nathan DA, Morton KE, Toomey MA, Rosenberg SA.

J Clin Oncol. 2015 Feb 20;33(6):540-9. doi: 10.1200/JCO.2014.56.2025. Epub 2014 Aug 25.

6.

Effect of transplant status in CD19-targeted CAR T-cell therapy: a systematic review and meta-analysis.

Nagle K, Tafuto B, Palladino Kim L, Parrott JS.

Med Oncol. 2018 Sep 11;35(11):144. doi: 10.1007/s12032-018-1204-6.

PMID:
30206753
7.

CAR-T cells : indications actuelles en pédiatrie et perspectives de développement.

Dourthe MÉ, Yakouben K, Chaillou D, Lesprit E, Dalle JH, Baruchel A.

Bull Cancer. 2018 Dec;105 Suppl 2:S147-S157. doi: 10.1016/S0007-4551(19)30045-1. French.

PMID:
30686353
8.

Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.

Sharma P, King GT, Shinde SS, Purev E, Jimeno A.

Drugs Today (Barc). 2018 Mar;54(3):187-198. doi: 10.1358/dot.2018.54.3.2776625. Review.

PMID:
29771253
9.

CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.

Singh N, Frey NV, Grupp SA, Maude SL.

Curr Treat Options Oncol. 2016 Jun;17(6):28. doi: 10.1007/s11864-016-0406-4. Review.

PMID:
27098534
10.

CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies.

Martyniszyn A, Krahl AC, André MC, Hombach AA, Abken H.

Hum Gene Ther. 2017 Dec;28(12):1147-1157. doi: 10.1089/hum.2017.126.

PMID:
29207878
11.

CAR T-cell therapy effective in B acute lymphoblastic leukaemia.

Wang M.

Lancet Oncol. 2017 Jun;18(6):e314. doi: 10.1016/S1470-2045(17)30364-9. Epub 2017 May 18. No abstract available.

PMID:
28528746
12.

Chimeric antigen receptor T-cell therapies for lymphoma.

Brudno JN, Kochenderfer JN.

Nat Rev Clin Oncol. 2018 Jan;15(1):31-46. doi: 10.1038/nrclinonc.2017.128. Epub 2017 Aug 31. Review.

PMID:
28857075
13.

Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.

Kochenderfer JN, Rosenberg SA.

Nat Rev Clin Oncol. 2013 May;10(5):267-76. doi: 10.1038/nrclinonc.2013.46. Epub 2013 Apr 2. Review.

14.

Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.

Oelsner S, Wagner J, Friede ME, Pfirrmann V, Genßler S, Rettinger E, Buchholz CJ, Pfeifer H, Schubert R, Ottmann OG, Ullrich E, Bader P, Wels WS.

Int J Cancer. 2016 Oct 15;139(8):1799-809. doi: 10.1002/ijc.30217. Epub 2016 Jun 11.

15.

The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis.

Zhou H, Luo Y, Zhu S, Wang X, Zhao Y, Ou X, Zhang T, Ma X.

BMC Cancer. 2018 Sep 26;18(1):929. doi: 10.1186/s12885-018-4817-4.

16.

CD19-Targeted CAR T Cells: A New Tool in the Fight against B Cell Malignancies.

Miller BC, Maus MV.

Oncol Res Treat. 2015;38(12):683-90. doi: 10.1159/000442170. Epub 2015 Nov 18. Review.

17.

The promise of CAR T-cell therapy in aggressive B-cell lymphoma.

Nair R, Neelapu SS.

Best Pract Res Clin Haematol. 2018 Sep;31(3):293-298. doi: 10.1016/j.beha.2018.07.011. Epub 2018 Aug 1. Review.

PMID:
30213399
18.

Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.

Makita S, Yoshimura K, Tobinai K.

Cancer Sci. 2017 Jun;108(6):1109-1118. doi: 10.1111/cas.13239. Epub 2017 May 25. Review.

19.

Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.

Cai B, Guo M, Wang Y, Zhang Y, Yang J, Guo Y, Dai H, Yu C, Sun Q, Qiao J, Hu K, Zuo H, Dong Z, Zhang Z, Feng M, Li B, Sun Y, Liu T, Liu Z, Wang Y, Huang Y, Yao B, Han W, Ai H.

J Hematol Oncol. 2016 Nov 25;9(1):131.

20.

CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia.

Davila ML, Kloss CC, Gunset G, Sadelain M.

PLoS One. 2013 Apr 9;8(4):e61338. doi: 10.1371/journal.pone.0061338. Print 2013.

Supplemental Content

Support Center